TOMI Environmental Solutions, Inc. (TOMZ): History, Ownership, Mission, How It Works & Makes Money

TOMI Environmental Solutions, Inc. (TOMZ): History, Ownership, Mission, How It Works & Makes Money

US | Industrials | Industrial - Pollution & Treatment Controls | NASDAQ

TOMI Environmental Solutions, Inc. (TOMZ) Bundle

Get Full Bundle:
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$25 $15
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99

TOTAL:

When you look at the environmental solutions space, does TOMI Environmental Solutions, Inc. (TOMZ)-a leader in disinfection technology-truly justify its valuation and growth narrative?

The company's distinctive Binary Ionization Technology® (BIT™) platform, which earned it the title of Disinfection and Decontamination Products Company of the Year 2025, drove a 95% sequential revenue increase in Q3 2025 to $2.0 million, maintaining a strong 61% gross margin in a tough market. Plus, with nearly 36% of Q3 revenue coming from international markets, the global traction for its recurring BIT™ Solution sales is undeniable, but what does the full picture-from its DARPA-backed history to its $15 million active sales pipeline-really tell you about the long-term investment risk?

We'll break down the full story of this key player, showing you exactly how its patented ionized hydrogen peroxide (iHP™) technology works and where its revenue streams, like the 21% year-to-date growth in solution sales, are coming from.

TOMI Environmental Solutions, Inc. (TOMZ) History

You want to understand the foundation of TOMI Environmental Solutions, Inc. (TOMZ) to better gauge its current strategy. The direct takeaway is that the company's history is a pivot from government-funded technology to a public, commercial decontamination leader, now focused on scaling its high-margin recurring revenue model despite recent liquidity concerns.

Given Company's Founding Timeline

Year established

The company was originally established in 2007, building the foundation for its disinfection and decontamination focus.

Original location

TOMI was founded in Beverly Hills, United States, though its current headquarters is in Frederick, Maryland.

Founding team members

A key figure in the company's early development and its founder is Dr. Halden Shane, who has served as the Chief Executive Officer.

Initial capital/funding

Specific initial capital is not public, but the company's first recorded funding round was a $60K Post IPO round on May 12, 2010.

Given Company's Evolution Milestones

Year Key Event Significance
Pre-2013 Binary Ionization Technology (BIT) developed under a DARPA grant. Established the core, proprietary technology (SteraMist) with a high-level government validation.
2013 SteraMist introduced to the commercial market. Marked the transition from a technology development project to a revenue-generating commercial entity.
2015 SteraMist BIT registered as an EPA hospital-healthcare disinfectant. A crucial regulatory win, allowing the technology to be marketed for the highly regulated hospital and healthcare sectors.
2021 Generated record annual revenue of $14.6 million. Signified peak market demand and commercial success, largely driven by heightened health concerns.
2025 (Q3) Reported revenue of $2.01 million with a 61% gross margin. Showed a strong 95% sequential revenue increase over Q2 2025, indicating a decisive turning point in sales momentum.
2025 (Nov) Filed a $50 million Universal Shelf Registration and secured a $20 million equity line. Strategic move to secure flexible capital for growth initiatives and address liquidity needs.

Given Company's Transformative Moments

The biggest shift for TOMI was moving its core technology, Binary Ionization Technology (BIT), from a government-funded research project to a commercial product line, SteraMist. This is defintely the foundation.

The company's business model is a classic 'razor-and-blade' approach, which is a major long-term driver. They sell the equipment (the razor) and then generate high-margin recurring revenue from the consumable BIT solution (the blade).

  • The 2025 Q3 results confirmed this model's strength: while total sales for the first nine months fell to $4.62 million from $6.67 million year-over-year, the high 61% gross margin remained robust, highlighting the value of the recurring solution sales.
  • A key recent win was securing purchase orders totaling $385,000 for 2025 from a major eye health company, which positions TOMI for future recurring revenue streams as the customer expands use of the SteraMist technology.
  • The most recent transformative moment is the capital restructuring in November 2025, where the company announced plans for a $50 million shelf registration and a $20 million equity line. This addresses the immediate financial pressure from a year-to-date operating loss of $(2.21) million and a Nasdaq warning about failing to meet the minimum $1.00 bid price and $2.5 million stockholders' equity requirements.

To be fair, the market is signaling risk, but management is taking clear action to secure capital for growth. You can see more detail on the current investor landscape in Exploring TOMI Environmental Solutions, Inc. (TOMZ) Investor Profile: Who's Buying and Why?

TOMI Environmental Solutions, Inc. (TOMZ) Ownership Structure

TOMI Environmental Solutions, Inc. (TOMZ) is a publicly traded, micro-cap company where control is clearly concentrated among its founders and executive leadership, with institutional investors holding a relatively small stake. This structure means strategic decisions are heavily influenced by the insider group, but still subject to the transparency and reporting requirements of a public listing.

Given Company's Current Status

TOMI Environmental Solutions, Inc. is a public entity trading on the Nasdaq Stock Exchange under the ticker symbol TOMZ. As of November 2025, the company has a market capitalization of approximately $15.7 million.

To be fair, the company is navigating a serious near-term risk: it received a deficiency letter from Nasdaq for non-compliance, specifically for having stockholders' equity below the required $2,500,000 threshold as of the third quarter of 2025. The operational momentum is there-Q3 2025 revenue was $2.012 million, a 95% sequential increase-but the balance sheet remains a key constraint. You need to watch their liquidity actions closely. Breaking Down TOMI Environmental Solutions, Inc. (TOMZ) Financial Health: Key Insights for Investors

Given Company's Ownership Breakdown

The ownership structure is top-heavy, with company insiders controlling the largest block of shares. This high insider ownership, at over one-third of the company, gives the leadership team significant voting power, which is a double-edged sword: it aligns management's interests with long-term performance but can also limit the influence of outside shareholders.

Shareholder Type Ownership, % Notes
Insiders (Executives & Directors) 35.46% The largest block, providing strong control over corporate strategy and voting matters.
Public/Retail Investors 59.87% Calculated as the remaining float, held by individual investors.
Institutional Investors 4.67% Held by 26 institutions, including Vanguard Group Inc and Geode Capital Management, Llc.

Given Company's Leadership

The company is steered by a small, focused executive team and a board that has seen recent appointments in late 2025 to strengthen its governance and financial expertise.

  • Halden S. Shane: Chief Executive Officer (CEO) and Chairman. He has served as Chairman since the company's inception, providing long-standing, founder-led direction.
  • Elissa J. Shane: Chief Operating Officer (COO) and Director. She is instrumental in managing the day-to-day operations and is also a board member.
  • David Vanston: Chief Financial Officer (CFO). Mr. Vanston brings over 25 years of international finance experience, which is defintely crucial as the company manages its liquidity challenges.

The Board of Directors also includes Francesco Fragasso and Harold W. Paul, who were elected in November 2025 at the Annual Meeting to three-year terms expiring in 2028. Paul, a securities specialist, and Fragasso, a former CFO of publicly traded companies, are key additions to help navigate the Nasdaq compliance risks and fortify financial oversight.

TOMI Environmental Solutions, Inc. (TOMZ) Mission and Values

TOMI Environmental Solutions, Inc. (TOMZ) is driven by a core purpose: to provide superior disinfection technology that creates a healthier, safer world. This commitment goes beyond sales, focusing on public health and environmental stewardship through its proprietary SteraMist platform.

You're investing in more than just a stock ticker; you're backing a company whose values are hardwired into its product, Binary Ionization Technology (BIT). For example, the company's recurring SteraMist solution sales were up 21% year-to-date in 2025, showing that their mission-critical product is generating steady, defensible revenue.

Given Company's Core Purpose

The company's cultural DNA is built on a dedication to efficacy and safety, aiming to be the premier solution in decontamination. This focus is what allows them to maintain a strong gross profit margin, which stood at 61% for Q3 2025. That's a high-quality business.

Official mission statement

TOMI Environmental Solutions' mission is centered on leveraging its proprietary technology to deliver superior environmental safety and hygiene across diverse sectors. They aim to combat pathogens and create a cleaner environment using their SteraMist technology. Mission Statement, Vision, & Core Values of TOMI Environmental Solutions, Inc. (TOMZ).

  • Provide disinfection and decontamination solutions for various industries.
  • Use SteraMist Binary Ionization Technology (BIT) to combat pathogens.
  • Create a cleaner and safer environment for healthcare, life sciences, and commercial spaces.

Honestly, their mission is simple: better disinfection, period.

Vision statement

The vision for TOMI Environmental Solutions is to establish its SteraMist technology as the global standard for disinfection and infection prevention. This is a clear roadmap for growth, which is why nearly 36% of their Q3 2025 revenue of $2.012 million was generated internationally.

  • Achieve global expansion into new markets and regions.
  • Invest in research and defintely development to enhance the SteraMist platform.
  • Establish industry leadership through innovation and customer satisfaction.

They want SteraMist everywhere, and their growing international footprint shows they are executing.

Given Company slogan/tagline

A company's tagline is its promise, and TOMI Environmental Solutions' is a concise statement of their core value proposition.

  • Innovating for a Safer World®

Their core values-Integrity, Innovation, Quality, Collaboration, and Responsibility-are the pillars supporting that promise, guiding decisions from R&D to customer service. The rising backlog, which climbed from $0.9 million at the end of Q3 2025 to $1.3 million by October 31, 2025, suggests customers trust their delivery on this safer world promise.

TOMI Environmental Solutions, Inc. (TOMZ) How It Works

TOMI Environmental Solutions, Inc. operates by manufacturing and selling advanced disinfection equipment and the proprietary solution needed to run it, creating a razor-and-blade model in the infection prevention market. The core value comes from its patented Binary Ionization Technology (BIT) platform, which transforms a low-concentration hydrogen peroxide solution into a powerful, residue-free germ-killing aerosol.

The company essentially sells the delivery system (the equipment) and the recurring consumable (the BIT Solution), ensuring a steady income stream. Recurring solution sales are a key growth driver, up 21% year-to-date through September 30, 2025.

Given Company's Product/Service Portfolio

Product/Service Target Market Key Features
SteraMist Environment System Hospitals, Pharmaceutical Facilities, Bio-Safety Labs Whole-room, hands-free decontamination; integrated system for large, critical spaces; uses patented ionized Hydrogen Peroxide (iHP).
SteraMist SteraPak+ Biohazard Remediation, Commercial/Office Buildings, Schools Portable, handheld unit for spot and surface disinfection; fast application with no residue or post-treatment wipe-down required.
BIT Solution (Consumable) All SteraMist Equipment Users Proprietary, low-concentration hydrogen peroxide solution; the recurring revenue driver; only active ingredient in the iHP process.
iHP Corporate Service Decontamination Government, Cruise Ships, Contracted Service Providers Full-service, emergency, or scheduled facility decontamination; leverages TOMI's expertise for high-stakes, large-scale projects.

Given Company's Operational Framework

TOMI's operational framework is built on manufacturing efficiency, a strong focus on recurring revenue, and strategic sales channel expansion. They are not just selling a machine; they are selling a process and a consumable, which is defintely a smarter model for long-term growth.

Here's the quick math: the company reported Q3 2025 revenue of $2.0 million with a strong gross profit margin of 61%, which underscores the efficiency of their operations and the high value placed on the proprietary technology.

  • Recurring Revenue Focus: Prioritizing the sale of the BIT Solution, which drives a stable, high-margin revenue stream after the initial equipment sale.
  • Global Distribution: Continued penetration into international markets, with nearly 36% of Q3 2025 revenue generated outside the US.
  • Partner Network Scaling: Expanding the SteraMist Pro Certified program and onboarding major service provider companies, like the Trauma and Casualty Team (T.A.C.T.), to scale service delivery without direct employment.
  • R&D for Application Expansion: Ongoing investment in research and development to broaden SteraMist applications across new sectors like food safety and biosecurity, capitalizing on regulatory changes like the FDA's broadened use of hydrogen peroxide.

The company also entered Q4 2025 with a sales order backlog of $1.3 million as of October 31, plus approximately $3 million in pending SteraMist Integration Contracts, signaling near-term revenue potential.

Given Company's Strategic Advantages

You need to know what makes this technology stand out in a crowded market. It boils down to a few key competitive moats that allow them to maintain that 61% gross margin.

  • Patented Binary Ionization Technology (BIT): The core intellectual property (IP) is the patented process of creating ionized Hydrogen Peroxide (iHP), which offers superior efficacy against pathogens, including bacteria, viruses, and spores.
  • Speed and Residue-Free Application: SteraMist delivers fast decontamination with minimal downtime, unlike harsh chemicals that require extensive aeration or leave corrosive residue. This is crucial for high-traffic, critical environments like hospitals and food processing facilities.
  • Regulatory and Industry Validation: The technology was originally developed under a Defense Advanced Research Projects Agency (DARPA) grant, lending significant credibility. Plus, the SteraMist brand was named 'Disinfection and Decontamination Products Company of the Year 2025.'
  • High-Margin Consumable Model: The recurring revenue from the proprietary BIT Solution is a significant advantage, ensuring customer lock-in and predictable, high-profit sales long after the initial equipment purchase.

If you're interested in the capital structure supporting this growth, you should read Exploring TOMI Environmental Solutions, Inc. (TOMZ) Investor Profile: Who's Buying and Why?

TOMI Environmental Solutions, Inc. (TOMZ) How It Makes Money

TOMI Environmental Solutions, Inc. primarily generates revenue through a classic 'razor-and-blade' model, selling its proprietary SteraMist equipment (the 'razor') and the recurring, consumable Binary Ionization Technology (BIT™) Solution (the 'blade') used in the equipment. This is supplemented by service revenue from its iHP Corporate Service Decontamination offerings and licensing fees, creating a revenue mix that balances large, upfront capital sales with predictable, high-margin recurring income.

TOMI Environmental Solutions, Inc.'s Revenue Breakdown

The company's revenue streams, as of the Q3 2025 financial results, are driven by two main product categories. While the exact percentage split for the quarter is not publicly detailed, the drivers are clear: Equipment sales provide the initial revenue spike, and Solution sales ensure long-term, high-margin stability. The Q3 2025 revenue was $2.01 million, a 95% sequential increase over Q2 2025, fueled by both streams.

Revenue Stream % of Total (Q3 2025 Driver) Growth Trend (YTD Sep 30, 2025)
SteraMist Equipment Sales Significant Driver Increasing (Key Q3 2025 Growth Factor)
Recurring BIT™ Solution Sales Core Recurring Revenue Increasing (21% YoY YTD)
iHP Service & Licensing Minor/Variable Stable/Targeted for Expansion

Business Economics

The core economic engine of TOMI Environmental Solutions is the high-margin, recurring revenue generated from the sale of its BIT™ Solution. This is a critical factor for financial analysts because it provides a more defensible and predictable revenue base than one-time equipment sales.

  • High Gross Margin: The company maintained a strong Gross Profit Margin of 61% in Q3 2025, which underscores the efficiency of its operations and the value of its proprietary technology.
  • Razor-and-Blade Model: The initial sale of SteraMist equipment (like the SteraPak or Environment Systems) creates a captive customer base for the consumable BIT™ Solution, which drives the sustained, recurring revenue. This is a defintely solid business model for long-term value.
  • International Expansion: International sales are a rapidly growing component, representing nearly 36% of Q3 2025 revenue, a significant jump from 20% in Q2 2025. This diversification helps mitigate reliance on any single domestic market.
  • Sales Backlog: As of October 31, 2025, the sales order backlog increased to $1.3 million, with an additional approximately $3 million in pending contracts, signaling strong near-term demand and future revenue potential.

TOMI Environmental Solutions, Inc.'s Financial Performance

While the company saw impressive sequential revenue growth in Q3 2025, the year-to-date figures reflect the challenging, capital expenditure-deferring economic environment that impacted the first half of the year. The focus is on reversing the year-over-year decline and moving toward profitability.

  • Q3 2025 Revenue Recovery: Net sales for the three months ended September 30, 2025, were $2.012 million, a 95% sequential increase over Q2 2025, although this was still lower than the $2.542 million reported in Q3 2024.
  • Year-to-Date Revenue Decline: For the nine months ended September 30, 2025, net sales were $4.619 million, a decrease from $6.670 million in the same period of 2024, primarily due to customers deferring capital expenditure projects earlier in the year.
  • Operating Loss Widening: The operating loss for the nine months ended September 30, 2025, widened to $(2.21 million), compared to an operating loss of $(956,000) for the same period in 2024. This shows that despite cost management efforts, top-line pressure has impacted the bottom line.
  • Net Loss: The net loss for the nine-month period was $(1.943 million), or $(0.10) per basic and diluted share. The consensus analyst estimate for the full FY2025 earnings per share is a loss of ($0.05).

For a deeper dive into the company's long-term strategy, you should review its Mission Statement, Vision, & Core Values of TOMI Environmental Solutions, Inc. (TOMZ).

TOMI Environmental Solutions, Inc. (TOMZ) Market Position & Future Outlook

TOMI Environmental Solutions is a niche player in the high-level disinfection market, strategically positioned to capture growth in regulated sectors like life sciences and food safety through its proprietary ionized Hydrogen Peroxide (iHP™) technology.

While the company's nine-month 2025 revenue of $4.62 million reflects a year-over-year decline in sales, the recent sequential rebound of 95% in Q3 2025 and a growing sales order backlog suggest a potential inflection point for its recurring revenue model.

Competitive Landscape

Company Market Share, % Key Advantage
TOMI Environmental Solutions, Inc. Est. 1.3% Patented Binary Ionization Technology (BIT™) for residue-free, rapid-cycle, low-concentration iHP™ disinfection.
STERIS plc Est. 22% Market leader with a comprehensive portfolio of Vaporized Hydrogen Peroxide (VHP) systems, strong global distribution, and full-service contract sterilization.
Ecolab (Bioquell) Not Publicly Disclosed Strong brand recognition, wide geographic presence, and a robust bio-decontamination equipment and services portfolio.

Opportunities & Challenges

You need to be a trend-aware realist, so let's map the near-term landscape. The global Vaporized Hydrogen Peroxide (VHP) Decontamination Equipment market is projected to reach approximately $485 million in 2025, so there is plenty of room for TOMI to grow its $15.7 million market cap business.

Opportunities Risks
Expansion of recurring revenue; BIT™ Solution sales are up 21% year-to-date 2025. Nine-month 2025 net sales of $4.62 million are down significantly from the prior year's $6.67 million.
International growth, with Q3 2025 revenue from global markets at nearly 36% (up from 20% in Q2). Sustained operating losses; Q3 2025 operating loss was $(321,000).
Growing sales order backlog of $1.3 million as of October 31, 2025, plus a pipeline of $3 million in pending integration contracts. Customer deferral of capital expenditure projects due to an uncertain economic environment.

Industry Position

TOMI Environmental Solutions, Inc. is a specialized innovator, not a volume leader, in the broader infection control market. Its strength is in its proprietary technology, which is a key differentiator against larger, more diversified competitors like STERIS plc. and Ecolab. The company focuses on high-stakes environments-Life Sciences, Healthcare, and Food Safety-where the non-residue and rapid-cycle nature of its SteraMist iHP™ technology is a critical advantage.

  • The company's gross profit margin remains strong at 61% for Q3 2025, showing the high intrinsic value of the technology and the consumable BIT™ Solution.
  • Recent FDA action broadening the permitted use of hydrogen peroxide significantly expands the potential application of SteraMist iHP, opening new markets like agriculture and biosafety.
  • The firm is actively strengthening its distribution channels and service network through programs like the SteraMist Pro Certified platform, a defintely smart move to scale a small team.
  • TOMI is actively addressing its capital needs with an equity purchase agreement that provides the right to sell up to $20 million in common stock over 24 months, giving it flexible capital for expansion.

To be fair, the company's small scale and volatile share price are real factors, but the focus on recurring solution sales is the right long-term play. You can read more about the core principles driving this strategy in the Mission Statement, Vision, & Core Values of TOMI Environmental Solutions, Inc. (TOMZ).

DCF model

TOMI Environmental Solutions, Inc. (TOMZ) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.